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Abstracts
CONCLUSION: Existing epidemiological data can pro-
vide tailored estimates of concrete benefits resulting from
improving the quality of anticoagulation.
CV2
A SIX YEAR FOLLOW-UP STUDY OF THE 
RELATIONSHIP BETWEEN MORTALITY, 
HOSPITALISATION AND ADHERENCE TO 
STATIN TREATMENT AFTER FIRST 
MYOCARDIAL INFARCTION
Wei L, Wang J, Davey P, MacDonald T
MEMO, University of Dundee, Dundee, UK
OBJECTIVE: To measure adherence to statins by pa-
tients treated for secondary prevention after myocardial
infarction and to estimate the effect of adherence on out-
come.
METHODS: We used a cohort design in the population
of Tayside, Scotland. Patients who experienced their first
MI between January 1990 and November 1995 were
identified from hospital discharge data. We used two out-
comes: mortality from any cause; hospitalization for re-
current MI. Adherence to statins was calculated as the
number of days for which statins were supplied divided
by the total number of days in the study for each patient.
Results were adjusted for age, sex, deprivation (as mea-
sured by the Carstairs code), serum cholesterol level, dia-
betes mellitus, cardiovascular drugs and other hospital-
ization using a Cox regression model.
RESULTS: Of 5590 patients enrolled in the cohort 1299
(23.2%) died during the follow-up period and 717
(12.8%) experienced at least one further MI. Only 7.7%
of patients used statins, and in comparison with non-us-
ers, these patients had more cardiovascular risk factors.
Compared to those not using statins, the adjusted relative
risk of mortality (95% CI) by quintiles of adherence was
0.65 (0.24–1.80) for the worst adherence quintile, 0.46
(0.06–3.43) for the second, 1.03 (0.37–2.88) for the
third, 0.19 (0.03–1.37) for the fourth, and 0.20 (0.09–
0.47) for the best adherence quintile. The adjusted rela-
tive risks of readmission by quintiles of adherence were
0.65 (0.24–1.79) for the worst adherence quintile, 0.47
(0.06–3.51) for the second, 1.05 (0.37–2.94) for the
third, 0.20 (0.03–1.41) for the fourth, and 0.21 (0.09–
0.48) for the best adherence quintile.
CONCLUSIONS: Statins were used infrequently and use
was a marker of cardiovascular risk. Despite such confound-
ing by indication, good adherence to treatment was associ-
ated with lower risks of further MI and lower mortality.
CV3
VASOPEPTIDASE INHIBITOR REDUCES
IN-HOSPITAL COSTS FOR CONGESTIVE
HEART FAILURE PATIENTS: RESULTS
FROM THE IMPRESS TRIAL
Eisenstein EL1, Nelson CL1, Simon TA2, Smitten AL3, Lapuerta 
P2, Mark DB1
1Duke Clinical Research Institute, Durham, NC, USA; 2Bristol-
Myers Squibb, Princeton, NJ, USA; 3Yale University School of 
Medicine, New Haven, CT, USA
OBJECTIVE: The IMPRESS clinical trial randomized pa-
tients with congestive heart failure to a daily regimen of
either omapatrilat or lisinopril. At 24 weeks, patients
randomized to omapatrilat had a significant reduction in
the primary endpoint of death, hospitalization, or discon-
tinuation of study drug for worsening heart failure (p 
.035) and fewer cardiac events (p  .04). This study
sought to determine the economic consequences of the
omapatrilat patient’s lower event rates.
METHODS: Economic outcomes were assessed in terms
of hospitalization events and their medical costs. Hospi-
tal event information was obtained via serious adverse
event forms, and hospital costs were evaluated by assign-
ing each hospitalization a DRG-based average cost for
physician and hospital services. Emergency room visits
for worsening heart failure were assigned costs equivalent
to those at Duke University Medical Center. All costs
were expressed in 1998 US dollars. Drug costs were not
assessed.
RESULTS: Patients in the omapatrilat (n  289) and lisi-
nopril (n  284) arms were evenly matched with regard
to baseline characteristics: age (both 64 years); NYHA
class III or IV heart failure (36% versus 38%); ejection
fraction (both 28%). There was no difference between study
arms in all-cause mortality. However, there was a trend to-
ward a greater number of all-cause hospitalizations in
the lisinopril versus omapatrilat patients (0.275 versus
0.215, p  .07). Differences in cardiac hospitalizations be-
tween lisinopril and omapatrilat were significant (0.208
versus 0.145, p  .03). There was a trend toward re-
duced medical costs at 24 weeks follow-up in omapatri-
lat-treated patients (US$1930 versus US$2002, p  .09).
Considering only cardiac medical costs, this trend toward
reduced medical costs became significant (US$1240 ver-
sus US$1442, p  .03).
CONCLUSIONS: In the first study to compare economic
outcomes in congestive heart failure patients treated with
omapatrilat and lisinopril, we found fewer hospitaliza-
tions and lower medical costs for omapatrilat patients at
24 weeks.
COST ESTIMATION
CE1
IMPACT OF CENSORED COST DATA ON THE 
OUTCOMES OF ECONOMIC EVALUATIONS
Oostenbrink JB, Al MJ, Rutten-van Mölken MM
Institute for Medical Technology Assessment, Rotterdam, 
Netherlands
OBJECTIVE: Patients in a clinical trial who withdraw
before the scheduled end date are a serious problem in
economic evaluations. The method to deal with data
from these patients can have important impact on out-
Abstracts 405
comes in terms of resource use and costs, especially when
withdrawal rates differ between treatment groups. The
aim of this study was to compare the impact of various
methods for dealing with censored data on the total costs
and on the difference in costs between treatment groups.
METHODS: Five methods for dealing with censored
data were applied to data from 519 patients with chronic
disease participating in a one-year randomized clinical
trial. These five methods are complete case analysis, lin-
ear extrapolation, hot-decking, predicted regression, and
multiple imputation.
RESULTS: Fifteen percent of the patients in treatment
group A and 21% of the patients in treatment group B with-
drew from the study before the scheduled end date. Mean
costs per patient varied from €889 (SE: 94) in the complete-
case analysis to €1400 (SE: 189) after predicted regression.
Cost differences between treatment groups varied from €14
in the complete-case analysis, to €243 after multiple impu-
tation, to €372 after predicted regression. Hot-decking,
multiple imputation and predicted regression were sensitive
to the selection of covariates.
CONCLUSION: The various methods had a consider-
able impact on total costs and on the difference in costs
between treatment groups. In economic evaluations more
attention should be paid to methods for dealing with cen-
sored patients and the impact of these different methods
on the CE-ratio.
CE2
HANDLING MISSING DATA IN STOCHASTIC 
COST-EFFECTIVENESS ANALYSIS: THE IMPACT 
OF IMPUTATION METHODS ON ESTIMATES OF 
THE PHYSICAL QUANTITIES OF MEDICAL CARE 
RESOURCE USE
Bell T1, Liu J1, Backhouse M2
1Research Triangle Institute, Raleigh-Durham, NC, USA; 
2Research Triangle Institute, Manchester, UK
OBJECTIVE: An issue that has recently received atten-
tion from health economists is how to handle the prob-
lem of missing data in stochastic cost-effectiveness analy-
sis. The purpose of this paper is to highlight the impact
that different approaches to the imputation of missing
data can have on estimates of the physical quantities of
medical care resource use.
METHODS: Medical care resource use data were col-
lected prospectively in a six-month RCT comparing two
treatments for a chronic condition that is characterized
by acute episodes. Two approaches of the multiple impu-
tation were used to address the problem of missing data.
Method A relied on imputing missing data for total costs
and then estimating the physical quantities of medical
care resource use. Method B relied on imputing missing
data for the physical quantities of medical care resource
use and then estimating total costs. Results for physician
and nurse visits and days in the hospital were reported.
RESULTS: The two multiple-imputation approaches pro-
duced different estimates of medical care resource use.
The average number of physician and nurse visits and
days in the hospital between the two groups were 5.7 vs.
5.3 physician visits, 1.0 vs. 0.9 nurse visits, and 4.0 vs.
4.7 days in the hospital determined with method A. The
average number of physician and nurse visits and days in
the hospital between the two groups were 6.0 vs. 6.3
physician visits, 1.2 vs. 1.3 nurse visits, and 4.0 vs. 5.0
days in the hospital using method B.
CONCLUSIONS: Medical care resource use estimates
are sensitive to the imputation approach. Method B
builds prediction models specifically for the utilization
components under the imputation, and results from the
imputed data sets may be less biased. It also provides
more flexibility for analyzing the cost components.
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THE COST OF UPPER GASTRODUODENAL 
ENDOSCOPY: AN ACTIVITY-BASED APPROACH
Crott R1, Makris N2, Barkun A3, Fallone C4
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OBJECTIVE: The cost of medical procedures is often un-
known, but is nevertheless crucial for setting reimburse-
ment and health-care policies. This study investigated the
cost of an upper gastrointestinal endoscopy in ambula-
tory adults in a large academic hospital in the province of
Québec, Canada from the perspective of the hospital.
METHODS: An activity-based costing methodology was
used to break down the endoscopy procedure into a number
of primary tasks to which were allocated resources used at
the department level (labor, equipment, and materials). Unit
costs per activity were calculated from detailed tracking of
items and factors used for performing each task.
RESULTS: The direct cost of performing an endoscopy
ranged from 62$Can (1Can$  0.75 EUR) for an unse-
dated, unbiopsied patient to 89$Can for a sedated, biop-
sied patient. Not included in this amount are separate re-
imbursement fees of 15$Can for biopsy analysis and
50$Can professional fees for the performing physician,
which are charged directly to the Ministry of Health. A
cost-volume function was constructed under two differ-
ent hypotheses of divisibility (sharing between clinical
units) or undivisibility of fixed equipment. This showed
an optimal unit cost per procedure starting at around
3000 procedures a year for the installed equipment. In-
corporating institutional overhead raises the cost of the
procedure substantially by an amount of 41$ as does the
use of non-reusable biopsy forceps, which adds about
63$Can to the total cost of the procedure.
CONCLUSION: Given the high proportion of overall
hospital-wide overhead in the total cost of the procedure,
allocation methods for these overheads in current hospi-
tal accounting systems should be improved in order to
obtain more precise estimates of the full cost of medical
procedures like upper gastrointestinal endoscopy. The
